2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Transplantation, Immunotherapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Radiation Therapy, Biological Processes, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Diseases, Bone Marrow Failure Syndromes, Immunology, GVHD, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, Study Population, Animal Model
PAPER

2322 Mocravimod enhances the graft-versus-leukemia effect by promoting donor T-cell priming in the lymph nodes

Nana Talvard-Balland, Patrick Sieber2, Hans D Menssen, MD, PhD3, Stephan Oehen4, Jens Hasskarl, MD, PhD5, Robert Zeiser, MD, PhD6
1 Medical Center - University of Freiburg, Freiburg, Germany
2 Medical Center - University of Freiburg, Freiburg, Germany
3 Priothera SAS, Saint-Louis, France
4 Priothera SAS, Saint-Louis, France
5 Medical Center - University of Freiburg, Freiburg, Germany, Priothera SAS, Saint-Louis, France
6 Medical Center - University of Freiburg, Freiburg, Germany

Background

Relapse remains the leading cause of treatment failure after allogeneic hematopoietic cell transplantation (allo-HCT) for acute myeloid leukemia (AML). Strategies to improve donor T-cell-mediated graft-versus-leukemia (GVL) activity while limiting graft-versus-host disease (GVHD) are needed. Mocravimod is an oral sphingosine-1-phosphate receptor (S1PR) modulator that regulates lymphocyte trafficking by preventing lymphocyte egress from lymph nodes and other secondary lymphoid organs and has demonstrated clinical potential for GVHD prevention after allo-HCT. Here, we investigated the impact of mocravimod on donor T-cell priming and anti-leukemic immunity in preclinical AML models.

Methods

Two independent murine AML allo-HCT models were used: an FLT3-ITD/MLL-PTD AML model and the C1498-OVA AML model, enabling tracking of leukemia-specific-(OVA dextramer?)-CD8? T-cell responses via SIINFEKL-loaded MHC-I dextramer staining.

Recipient mice received allogeneic bone marrow (BM) transplantation together with AML cells at day 0, followed by infusion of donor-derived allogeneic T cells at day 2 post-allo-HCT to induce GVL responses. Mocravimod (3mg/Kg) was administered daily by oral gavage starting 7 days before allo-HCT and continued after allo-HCT. Leukemia burden, survival, donor T-cell responses and GVHD pathology were assessed.

Results

In the C1498-OVA model, mocravimod significantly increased the absolute number of leukemia-specific-(OVA dextramer?)-CD8? T cells in lymph nodes (P=0.02) after allo-HCT. In both lymph nodes and BM, these cells exhibited enhanced cytotoxic potential, with increased expression of granzyme B and FAS ligand, indicating improved tumor-specific T-cell priming and effector function rather than immune suppression. In the FLT3-ITD/MLL-PTD AML model, mocravimod treatment in combination with allo-HCT and donor T-cell transfer significantly improved overall survival compared with allo-HCT alone (P<0.0001) and reduced leukemic burden in BM and peripheral blood (P<0.0001). Importantly, mocravimod did not improve survival in mice receiving allo-HCT without donor T cells, indicating that the therapeutic effect was mediated through donor immune responses rather than a direct cytotoxic effect of mocravimod on leukemic cells. GVHD histology scoring demonstrated reduced GVHD severity in target organs, including colon, liver, and small intestine compared to vehicle-treated mice. Furthermore, donor T cells isolated from mocravimod-treated mice retained potent anti-leukemic immunity upon tumor re-challenge compared with donor T cells from vehicle-treated mice (P=0.0002), demonstrating durable and functional GVL responses.

 Conclusions

Mocravimod enhances leukemia-specific-(OVA dextramer?)-CD8? T-cell responses after allo-HCT, resulting in improved AML control and robust GVL immunity while reducing GVHD pathology. These findings demonstrate that mocravimod can enhance the GVL effect, while limiting GVHD. This separation of GvL from GvHD provides a strong preclinical rationale for evaluating mocravimod as a post-transplant maintenance strategy to reduce relapse risk in AML, which is currently tested in a randomized phase 3 trial (NCT05429632).

Nana Talvard-Balland: No relevant conflicts of interest to declare.